Riskpilot← Back to searchSign inGet full accessAtopalen Pharmaci AB
ABIn liquidationOrg 5568026156Economic activity was not specified by tax authority · NACE 0000Est. 20100 employees
Revenue 2023
SEK 0
EBITDA margin
—
-104% vs 2022
Equity ratio
98.8%
Financial strength
Net profit 2023
SEK 6,2M
+31944% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -40K | -104% |
| Net profit | SEK 6,2M | +31944% |
| Total assets | SEK 18M | +45% |
| Equity | SEK 17,8M | +48% |
| Employees | 0 | — |
Legal name
Atopalen Pharmaci AB
Org number
5568026156
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
20 mars 2010
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn externa firmatecknarna
Company purpose
Företaget ska äga och förvalta kapital samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −28 | −17 | −18 | −19 | −40 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −28 | −17 | −18 | −19 | −40 |
| Net financials | 680 | — | — | — | 6 246 |
| Profit before tax | 651 | −17 | −18 | — | — |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | 651 | −17 | −18 | −19 | 6 206 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 12 438 | 12 422 | 12 422 | 12 403 | 18 020 |
| Equity | 12 428 | 12 411 | 12 394 | 11 999 | 17 798 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 9 | 11 | 28 | 404 | 221 |
| Total debt | 9 | 11 | 28 | 404 | 221 |
EBITDA margin
-3974000.0%
This company
15.8%
Market median
-25151999% vs market
20192023
Equity ratio
98.8%
This company
38.2%
Market median
+159% vs market
20192023
Return on equity
34.9%
This company
18.4%
Market median
+90% vs market
20192023
Net profit margin
620637600.0%
This company
8.1%
Market median
+7662192493% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
LB External Signatory | External Signatory | 2024 |
IM External Signatory | External Signatory | 2024 |
BJ External Signatory | External Signatory | 2024 |
UM External Signatory | External Signatory | 2024 |
EJ Liquidator | Liquidator | 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Chairman | 2022 – 2024 | |
| Deputy Board Member | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Atopalen Pharmaci AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Birgitta Killgren Jonsson | External Signatory | 0 companies |
| Inger Margareta Dahle | External Signatory | 0 companies |
| Bengt Junior Niklas Nygårds | External Signatory | 0 companies |
| Ulrika Margareta Ahlholm | External Signatory | 0 companies |
| Emma Johanna Karin Carlstedt Haga | Liquidator | 0 companies |
| Anders Peter Gösta Hagberg | Chairman | 0 companies |
| Carl Gustav Magnus Nilsson | Deputy Board Member | 0 companies |
| Hanna Hagberg | Board of Directors | 0 companies |